A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes - Barrington, P; Chien, J Y; Showalter, H D (Diabetes, Obesity & Metabolism, 2011)
et al.